05/19/2026
Great Day 2 at !
Another day of learning, networking and catching up with old friends!
Exciting to see so much evolve since last year APA, with regards to new treatments available in mental health.
Some key takeaways from today:
1. If patients with schizophrenia that are treated with Xanomeline-Trospium (Cobenfy) experience GI side effects, best way to overcome this is to titrate up to maximum dose (125 mg/30 mg), as the higher dose of Trospium (30 mg) helps mitigate peripherally the GI adverse effects.
2. In patients with treatment resistant schizophrenia, clozapine is 30% effective in this population, with olanzapine coming 2nd at 7-9%.
3. Over 50% of Bipolar patients have a co-morbid metabolic condition, and there crucial to liase with primary care physicians to provide comprehensive care for this patient population, both medically and psychiatricslly.
More Research
More Evidence
Better Patient Care